EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell Transplantation

Elisa Tarozzi iD, Katja Seipel iD, Inna Shaforostova, Marie-Noelle Kronig, Ulrike Bacher iD, Thomas Pabst iD

Cancers · 26.05.2026 · 18 (11) · 1734

DOI: 10.3390/cancers18111734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 26.05.2026. Verfasst von Elisa Tarozzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Germline variants of the immune checkpoint receptor CTLA4 may modulate T-cell activation, potentially influencing post-transplant immune reconstitution and clinical outcomes.

Methods

In this retrospective single-center study, 140 AML patients who underwent ASCT were stratified into three groups according to the CTLA4 rs231775 geno-types A17hom, T17Ahet, and T17hom. Clinical outcomes, including overall survival (OS) and progression-free survival (PFS), were evaluated. Multivariate analysis was performed to adjust for known prognostic covariates.

Results

Baseline clinical characteristics varied according to CTLA4 genotype with a higher proportion of favorable cytogenetic risk in A17hom carriers. Comparative analysis revealed differences in survival rates, with superior outcomes in A17hom carriers. In multivariate analysis directional trends persisted across all endpoints.

Conclusion

The prognostic impact of CTLA4 rs231775 on post-ASCT outcomes suggests that T-cell inhibitory signaling may contribute to anti-leukemic immune surveillance in the autologous setting. These findings provide a rationale for investigating CTLA4 inhibition as consolidation therapy following ASCT in future prospective studies, particularly in T17hom carriers, who may harbor a less favorable immune profile. CTLA4 genotyping at diagnosis may represent a practical tool to support risk stratification in AML.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemia (AML)allogeneic transplantation (allo-HSCT)antileukemic immune surveillanceautologous stem cell transplantation (ASCT)cytotoxic T-lymphocyte-associated protein 4 (CTLA4)overall survival (OS)progression-free survival (PFS)single-nucleotide polymorphism (SNP)

Autor:innen und Institutionen

  • Department of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland.
  • Department for Biomedical Research (DBMR), Bern University, 3008 Bern, Switzerland.
  • Department of Hematology, University Hospital Bern, 3010 Bern, Switzerland.

ORCID-Profile: Elisa Tarozzi, Katja Seipel, Ulrike Bacher, Thomas Pabst

Zitieren

APA

Tarozzi, E., Seipel, K., Shaforostova, I., Kronig, M. N., Bacher, U., & Pabst, T. (2026). Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell Transplantation. Cancers, 18(11), 1734. https://doi.org/10.3390/cancers18111734

Vancouver

Tarozzi E, Seipel K, Shaforostova I, Kronig MN, Bacher U, Pabst T. Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell Transplantation. Cancers. 2026;18(11):1734. doi:10.3390/cancers18111734

BibTeX
@article{Tarozzi2026,
  author = {Tarozzi, Elisa and Seipel, Katja and Shaforostova, Inna and Kronig, Marie-Noelle and Bacher, Ulrike and Pabst, Thomas},
  title = {Clinical Impact of the CTLA4 rs231775 Polymorphism in Acute Myeloid Leukemia Treated with Autologous Stem Cell Transplantation},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1734},
  doi = {10.3390/cancers18111734}
}
Kostenlos starten →